GSK's sirukumab headed for RA submission

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it plans to submit regulatory applications next year for sirukumab ( CNTO 136) to treat rheumatoid arthritis. The company said the human IgG1 kappa mAb against IL-6 produced "positive" top-line results in three Phase III trials to treat moderate to severe RA.

GSK spokesperson Kathleen Cuca declined to disclose whether sirukumab met the studies' primary endpoints, and said GSK intends to present the results next year. ...